Athletic Intervention After THoracic surgEry for luNg cAncer: a Pilot Study

The aim of this pilot study is to assess in a preliminary cohort the effect of an active athletic training program in improving respiratory function parameters as well as quality of life after resective surgery for lung cancer. Ten patients (5 males and 5 females) who underwent lung resection for cancer will be identified and selected based on their high PS, the absence of comorbidity and need of adjuvant therapy based on post operative TNM disease stage IA and after multidisciplinary evaluation by GINT. The study will last 6 months for each of the 10 subjects enrolled during 12 months. The subsequent follow up for each patient will last 6 months. Each patient will be addressed to a 6-month athletic program under the supervision of a motor scientist to evaluate if this active intervention could positively impact on the recovery and improvement of pulmonary function as well as on quality of life after surgery for cancer. Moreover, although a pilot study, we will also evaluate stratify patients based on their gender and age to evaluate potential impact of demographic features.

Study participants will be recruited at Fondazione IRCCS Policlinico San Matteo, SC Pneumologia among those patients affected by lung cancer and addressed to surgery with a curative setting. After surgery each case will be rediscussed multidisciplinary and patients with higher performance status, defined by ECOG score 0 and CCI score from 1 to 4, will be selected for the study.

Specifically the ECOG Performance Status Scale describes a patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability. An ECOG score of 0 identifies a fully active person, able to perform all pre-disease services without limitations. The Charlson Comorbidity Index (CCI) is used to classify comorbid conditions which may influence mortality risk. The severity of comorbidity from mild (CCI scores of 1-2) to moderate (CCI scores of 3-4) is used for the selection of patients in the study. Higher scores indicate a more severe condition and consequently, a worse prognosis.

Data obtained will be compared to storage data and published ones on patients with the same features of those enrolled in the study, who are addressed on to follow up after surgery.

Patients will be followed by motor scientists during their active training. Exercises could be slightly modified and each modification will be reported to CRF. In case of need of relevant modification of the training exercises the patient will leave the study.

The patient will enter the study 30 days after surgery. The first screening visit will encompass spirometry, DLCO analysis and VO2 max calculation. Patients will also undergo electrocardiogram (ECG) as per clinical practice, standard routine blood exam and clinical visit. Then the patient will enter the trial and subsequent controls, similar to the first one will be done at 3rd and 6th month, at the end of the program. At the same intervals a total body CT scan will be performed, as per clinical practice. After the end of the active interventional study, patients will continue the standard follow up procedures according to national and international guidelines.

The primary endpoint will be the change of pulmonary function VO2 max) measured at baseline and at the 6 th month of the study. It is defined as the amount of oxygen consumed while sitting at rest and is equal to 3.5 ml O2 per kg body weight x min.

Secondary endpoint will be:

• the change of pulmonary function (FEV1 and DLCO and VO2 max) measured at baseline, at the 3 rd and at the 6 th month of the study. The latter is defined as the amount of oxygen consumed while sitting at rest and is equal to 3.5 ml O2 per kg body weight x min.
• The quality of life will be assessed by the EORTC QLQ-C30 (vers. 3) Questionnaire a 30-item instrument designed to measure quality of life in all cancer patients [21].
• Improvement in caloric consumption measured by metabolic equivalents (MET).

Although being a pilot study, demographic exploratory outcomes would be assessed. Results will be analysed to evaluate if observed differences in outcomes could be related to gender and/or age of the subjects since it is conceivable that the two variables could affect athletic performances and primary and secondary outcomes.

Inclusion criteria

• Male and female ≥18 years old
• Patient underwent a curative surgical treatment of NSCLC (stage IA according to AIOM guidelines, website https://www.iss.it/documents/20126/8403839/LG149_Polmone_agg2024.pdf/9e22916b-799c-3966-7dc9-01762112ce94?version=1.0&t=1732534604319)
• First whole body CT scan after surgery (executed according to routine procedures two months after surgery) negative for cancer recurrence
• Patients highest scores of performance status, defined after multidisciplinary evaluation by Interdisciplinary Group for Tho-racic Neoplasms (GINT) using ECOG Performance Status Scale and Charlson Comorbidity Index (CCI). Subject with ECOG score 0 and CCI score from 1 to 4 is eligible.
• Informed Consent as documented by signa-ture

Exclusion criteria

• Requirement of adjuvant treatment
• Women who are pregnant or breast feeding
• Intention to become pregnant during the course of the study,
• Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the en-tire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases. (Female participants who are surgically sterilised/hysterectomised or post- meno-pausal for longer than 2 years are not considered as being of child bearing potential)
• Other clinically significant concomitant disease states (e.g., respiratory failure, COPD, interstitial lung disease, hepatic dysfunction, cardiovascular disease)
• Known or suspected non-compliance, drug or alcohol abuse,
• Inability to follow the procedures of the study
• Participation in another study with investigational asset within the 30 days preceding and during the present study
• Enrolment of the investigator, his/her family members, em-ployees and other dependent persons